Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
May 03, 2023 at 07:50 AM EDT
LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce that Dr. Carol Routledge, Chief Medical and Scientific Officer, will deliver a poster presentation at the 34th CINP World Congress of Neuropsychopharmacology in Montreal, Canada which is taking place on May 7-10, 2023.
The poster will showcase positive data from the Company’s Phase IIa trial of SPL026, the first placebo-controlled study of a short-duration psychedelic for the treatment of Major Depressive Disorder (“MDD”). The trial investigated the efficacy, safety and tolerability of a 21.5mg intravenous dose of SPL026, a proprietary synthetic formulation of N,N-Dimethyltryptamine (“DMT”), with supportive therapy in 34 patients with moderate/severe MDD.
Title: Efficacy, Safety and Tolerability of SPL026 with Support Therapy in Patients with Major Depressive Disorder
About Small Pharma
Small Pharma Inc. & Investor Relations:
The TSX Venture Exchange (“TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.